secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001104659-24-038705
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune names Sushil Patel CEO effective April 1; Astley-Sparke becomes Executive Chairman
--------------------------------------------------------------------------------

- Dr. Sushil Patel appointed CEO effective April 1, 2024; previously Chief Strategy Officer.
- Philip Astley-Sparke transitions from CEO to Executive Chairman; Dieter Weinand becomes Lead Independent Director.
- Robert Coffin moves to Founder & Chief Scientist advisory role; Paul Bullock promoted to Chief Manufacturing Officer.
- Colin Love (COO) retiring May 31; Pamela Esposito and Tanya Lewis leave executive roles but remain advisors.
- Company on track to submit RP1 BLA in 2H 2024 for anti-PD1 failed melanoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/tm249769d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-038705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer